iTeos Therapeutics (NASDAQ:ITOS – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wedbush in a research report issued on Wednesday, Benzinga reports. They presently have a $33.00 price target on the stock. Wedbush’s target price suggests a potential upside of 275.00% from the stock’s current price.
Separately, HC Wainwright decreased their target price on iTeos Therapeutics from $54.00 to $44.00 and set a “buy” rating for the company in a research note on Wednesday, August 9th.
iTeos Therapeutics Trading Down 1.0 %
iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) last posted its earnings results on Tuesday, August 8th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.07. iTeos Therapeutics had a negative return on equity of 4.42% and a net margin of 9.02%. As a group, sell-side analysts predict that iTeos Therapeutics will post -3.19 earnings per share for the current fiscal year.
Insider Transactions at iTeos Therapeutics
In other news, insider Boxer Capital, Llc sold 350,000 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $16.26, for a total transaction of $5,691,000.00. Following the completion of the transaction, the insider now directly owns 1,804,058 shares of the company’s stock, valued at $29,333,983.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Matthew Gall purchased 5,000 shares of iTeos Therapeutics stock in a transaction that occurred on Thursday, October 12th. The stock was purchased at an average cost of $8.37 per share, with a total value of $41,850.00. Following the completion of the transaction, the chief financial officer now owns 19,429 shares of the company’s stock, valued at approximately $162,620.73. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Boxer Capital, Llc sold 350,000 shares of the stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $16.26, for a total value of $5,691,000.00. Following the transaction, the insider now directly owns 1,804,058 shares of the company’s stock, valued at $29,333,983.08. The disclosure for this sale can be found here. 10.20% of the stock is owned by insiders.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of ITOS. Swiss National Bank boosted its position in iTeos Therapeutics by 7.7% during the first quarter. Swiss National Bank now owns 33,400 shares of the company’s stock valued at $1,075,000 after purchasing an additional 2,400 shares during the last quarter. JPMorgan Chase & Co. boosted its position in iTeos Therapeutics by 286.3% during the first quarter. JPMorgan Chase & Co. now owns 226,674 shares of the company’s stock valued at $7,295,000 after purchasing an additional 167,992 shares during the last quarter. Bank of New York Mellon Corp raised its stake in iTeos Therapeutics by 82.0% in the first quarter. Bank of New York Mellon Corp now owns 186,800 shares of the company’s stock valued at $6,011,000 after buying an additional 84,186 shares during the period. MetLife Investment Management LLC raised its stake in iTeos Therapeutics by 58.5% in the first quarter. MetLife Investment Management LLC now owns 12,678 shares of the company’s stock valued at $408,000 after buying an additional 4,679 shares during the period. Finally, Rhumbline Advisers raised its stake in iTeos Therapeutics by 59.0% in the first quarter. Rhumbline Advisers now owns 43,373 shares of the company’s stock valued at $1,396,000 after buying an additional 16,099 shares during the period. 97.16% of the stock is owned by institutional investors and hedge funds.
iTeos Therapeutics Company Profile
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Further Reading
- Five stocks we like better than iTeos Therapeutics
- 3 Healthcare Dividend Stocks to Buy
- 3 High Dividend Stocks To Beat Treasury Yields
- How to Invest in Pharmaceutical Companies
- United Airlines Shares Fall Despite Solid Quarter
- What is a Bond Market Holiday? How to Invest and Trade
- Housing Starts Up, Homebuilders Down as Mortgage Rates Soar
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
